Currently out of the existing stock ratings of Rick Wise, 238 are a BUY (81.79%), 52 are a HOLD (17.87%), 1 are a SELL (0.34%).

Rick Wise

Work Performance Price Targets & Ratings Chart

Analyst Rick Wise, currently employed at STIFEL, carries an average stock price target met ratio of 66.04% that have a potential upside of 18.37% achieved within 206 days.

Rick Wise’s has documented 589 price targets and ratings displayed on 29 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on ABT, Abbott Laboratories at 17-Apr-2025.

Wall Street Analyst Rick Wise

Analyst best performing recommendations are on TNDM (TANDEM DIABETES CARE).
The best stock recommendation documented was for TNDM (TANDEM DIABETES CARE) at 2/5/2024. The price target of $24 was fulfilled within 1 day with a profit of $1.1 (4.8%) receiving and performance score of 48.03.

Average potential price target upside

of $46.16 (23.39%) on BDX (BECTON DICKINSON AND COMPANY).
of $38.33 (17.64%) on SYK (STRYKER).
of $31.47 (12.88%) on ISRG (INTUITIVE SURGICAL).

BAX Baxter International BDX Becton Dickinson and Company BSX Boston Scientific Corp CNMD CONMED EW Edwards Lifesciences Corp HRC Hill-Rom Holdings ISRG Intuitive Surgical LIVN LivaNova PLC LMAT LeMaitre Vascular MASI Masimo MDT Medtronic PLC OM Outset Medical SILK Silk Road Medical SYK Stryker ZBH Zimmer Biomet Holdings ABT Abbott Laboratories ATRC AtriCure JNJ Johnson & Johnson KIDS Orthopediatrics Corp LUNG Pulmonx Corp TMCI Treace Medical Concepts VRAY ViewRay RSLS ReShape Lifesciences AORT Artivion OBLN Obalon Therapeutics TRXC Asensus Surgical AVNS Avanos Medical TNDM Tandem Diabetes Care PROF Profound Medical Corp

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Matt Miksic (BARCLAYS)